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Abstract
Background: Retroperitoneal fibrosis (RPF) is a rare fibroinflammatory disease that leads to
hydronephrosis and renal failure. In a case-control study, we have recently shown that asbestos
exposure was the most important risk factor for RPF in the Finnish population. The aim of this
study was to evaluate the relation of asbestos exposure to radiologically confirmed lung and pleural
fibrosis among patients with RPF.
Methods: Chest high-resolution computed tomography (HRCT) was performed on 16 unexposed
and 22 asbestos-exposed RPF patients and 18 asbestos-exposed controls. Parietal pleural plaques
(PPP), diffuse pleural thickening (DPT) and parenchymal fibrosis were scored separately.
Results: Most of the asbestos-exposed RPF patients and half of the asbestos-exposed controls had
bilateral PPP, but only a few had lung fibrosis. Minor bilateral plaques were detected in two of the
unexposed RPF patients, and none had lung fibrosis. DPT was most frequent and thickest in the
asbestos-exposed RPF-patients. In three asbestos-exposed patients with RPF we observed
exceptionally large pleural masses that were located anteriorly in the pleural space and continued
into the anterior mediastinum.
Asbestos exposure was associated with DPT in comparisons between RPF patients and controls
(case-control analysis) as well as among RPF patients (case-case analysis).
Conclusion: The most distinctive feature of the asbestos-exposed RPF patients was a thick DPT.
An asbestos-related pleural finding was common in the asbestos-exposed RPF patients, but only a
few of these patients had parenchymal lung fibrosis. RPF without asbestos exposure was not
associated with pleural or lung fibrosis. The findings suggest a shared etiology for RPF and pleural
fibrosis and furthermore possibly a similar pathogenetic mechanisms.
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Background
Retroperitoneal fibrosis (RPF), or Ormond's disease, is a
rare condition with fibrosis covering the abdominal aorta
and the ureters. The etiology of RPF is generally unknown.
It has been proposed that approximately one-third of RPF
cases develop secondarily to aortic aneurysm, abdominal
infections or surgery and as a side effect of several drugs,
especially methysergide and other ergot derivates [1-3].
Asbestos is known to cause diffuse pleural thickening
(DPT) and parietal pleural plaques [4]. High-level asbes-
tos exposure may lead to the development of clinically
detectable lung fibrosis (asbestosis) [5]. We have recently
shown that asbestos exposure is one of the most impor-
tant single risk factors for RPF, accounting for approxi-
mately 20% of all RPF cases in the Finnish population
[6,7]. The aim of this study was to determine whether RPF
patients have pleural or lung fibrosis and to assess the
relations between asbestos exposure and intrathoracic
fibrotic changes in RPF patients. Furthermore we evalu-
ated the susceptibility for pleural and lung fibrosis among
asbestos-exposed RPF patients and asbestos-exposed con-
trols.
Subjects and methods
Study population
This material was part of our case-control study including
43 persons with RPF and 179 randomly assigned controls
matched for year of birth, gender and central hospital dis-
trict in Finland [6]. The diagnosis of RPF required the pres-
ence of the typical clinical condition–fibrosing mass
covering the abdominal aorta and other retroperitoneal
structures–and either histological confirmation (35 of 43
persons) or a follow-up of at least 1 year in order to rule
out retroperitoneal malignancies (8 of 43 persons).
All of the participants were interviewed for medical his-
tory and asbestos exposure. The cumulative exposure to
asbestos dust was estimated using fiber-years (40-hour
shift per week at an average dust level of 1 fiber/ml for 1
year) and graded as follows: no significant asbestos expo-
sure; slight exposure (asbestos exposure <10 fiber-years)
and moderate-to-high exposure (asbestos exposure ≥ 10
fiber-years). Exposure was assessed by an occupational
health physician with special expertise in the evaluation
of asbestos exposure, the physician was blinded in terms
of the case-control status of the participants. The details of
the data collection have been given in our previous report
[6].
We asked all of the unexposed and exposed patients with
RPF and the controls with moderate-to-high asbestos
exposure to participate in a study evaluating pleural and
lung fibrosis with chest high-resolution computed tomog-
raphy (HRCT). The Ethics Committee of the Tampere
University Hospital approved the study protocol.
Participation rate and demographic features
Altogether 38 (88%) of the patients with RPF and 18
(86%) of the asbestos-exposed controls were willing to
participate. None of the 5 RPF patients who refused to
participate in the HRCT study had notable asbestos expo-
sure, which was also the main reason for their refusal.
The mean time since first asbestos exposure was 41.4 (SD
12.1) years for the RPF patients and 42.4 (8.9) years for
the controls (Table 1).
Imaging
The HRCT was carried out in seven central hospitals. The
HRCT scans consisted of 1-mm slices at 20-mm intervals
from the first rib to the costophrenic angle in the prone
position and with full inspiration. No contrast medium
was used. The images were printed at two separate settings
appropriate for viewing the lung parenchyma or the medi-
astinum and the pleura, the settings depending on the
scanner used.
Image analysis
All of the images were reviewed by two experienced tho-
racic radiologists. The reviewers were blinded to all medi-
cal information except the participants' names and
identification numbers, which were printed on the films.
The images were scored by consensus reading. Lung fibro-
sis, parietal pleural plaques and diffuse pleural thickening
(DPT) were scored separately (additional files 1 and 2).
The scoring was modified from our earlier classification
systems [8,9]. Model images were not used, and the scor-
ing was carried out in two sessions within one week.
Table 1: Demographic and exposure characteristics of the patients with retroperitoneal fibrosis and asbestos-exposed controls.
RPF Asbestos exposure Gender men/woman Age Pack-years of smoking Age at diagnosis of RPF
mean SD mean SD mean SD
Yes No 9/7 61.9 9.7 20.4 18.8 55.5 9.6
Yes Yes 19/3 64.1 9.4 27.0 17.4 54.9 8.0
No Yes 18/0 66.0 7.7 22.4 27.1 NA
(RPF = retroperitoneal fibrosis, NA = not applicable)Orphanet Journal of Rare Diseases 2008, 3:29 http://www.ojrd.com/content/3/1/29
Page 3 of 10
(page number not for citation purposes)
Measurements of the maximum DPT thickness were per-
formed subsequently in one session. A definitely abnor-
mal finding that could be related to asbestos exposure was
rated class 1 for DPT (unilateral DPT <5 mm) and class 2
for pleural plaques (bilateral plaques on less than half of
the slices) and lung fibrosis (at least 2 abnormal findings
on both sides in several slices) (additional files 1 and 2).
Classification of the pleural abnormalities
Pleural plaques are discrete areas of fibrous tissue limited
to the parietal pleura, whereas diffuse pleural thickening
or visceral pleural fibrosis is much more widespread and
usually extends into the costophrenic angles [10-12].
Pleural plaques were diagnosed as sharply defined thick-
enings located internally with respect to a visible rib seg-
ment in the chest walls, paravertebral regions, or on the
diaphragmatic surfaces, with or without calcification.
Pleural thickening was classified as DPT if it appeared as a
smooth, uninterrupted density with ill-defined margins
and with extension of more than one-fourth of the pleural
surface. Parenchymal bands extending from the pleural
thickening to the lung parenchyma, rounded atelectasis,
and the involvement of the interlobar fissures was used to
differentiate DPT from pleural plaques. Rounded atelecta-
sis was defined as a round or oval mass abutting the pleu-
ral surface and associated with the curving of pulmonary
vessels or bronchi into the edge of the lesion [11]. The
maximum thickness of the DPT was measured from the
slices transversal with the thoracic wall.
Statistical analysis
For the statistical analysis we combined the two asbestos-
exposed RPF patient groups. The groups were compared
using the Kruskal-Wallis and the Mann-Whitney tests, as
appropriate. An ordinal logistic regression analysis was
performed to assess the risk factors for DPT, pleural
plaques and lung fibrosis in the asbestos-exposed patients
and controls. The factors evaluated were the presence of
RPF, age at the time of the HRCT, smoking in pack years,
and the pleural plaque, DPT and lung fibrosis grade, as
appropriate. The analysis was based on proportional odds
(i.e. constant odds ratio across ordered categories of the
response variable: odds of having a diagnostic score × or
higher relative to having a score below ×). The outcome
variable was the radiological finding categorized into four
classes. The results of the ordinal logistic regression anal-
ysis therefore indicated susceptibility to the development
of fibrotic changes, given asbestos exposure. Statistical sig-
nificance was assessed using the likelihood ratio test. In
addition, the susceptibility for asbestos-related pleural
fibrosis among the RPF patients was evaluated in a case-
case setting [13] using logistic regression analysis. All of
the calculations were carried out with STATA 8.0 software
(Stata Corporation, College station, TX, USA)
Results
Parietal pleural plaques
The unexposed RPF patients had only minor pleural
plaques (≤ class 2), and the differences between this group
and the asbestos-exposed groups were statistically signifi-
cant (Figure 1, Table 2).
More than 60% of the asbestos-exposed RPF patients and
half of the exposed controls had bilateral pleural plaques
(Figure 1, Table 2), and almost half of them had wide-
spread plaques in class ≥ 3. The frequency and quantity of
the pleural plaques were similar in both of the asbestos-
exposed groups. There were no differences between the
asbestos-exposed cases and controls with respect to sus-
ceptibility to the development of parietal pleural plaques
in the ordinal logistic regression analysis. Out of the stud-
ied variables, only lung fibrosis was associated with pari-
etal pleural plaques (OR 3.78, 95% CI 1.52–9.43). The
grade of pleural plaques was not related to age, smoking
history, or DPT grade (additional file 3). In the case-case
analysis, the OR for pleural plaques related to asbestos
was 12.2 (Table 3).
Diffuse pleural thickening
DPT occurred more frequently among the RPF patients
with asbestos exposure than among the unexposed
patients (P = 0.045). There were no differences between
the asbestos-exposed RPF patients and controls (P =
0.190) and none of the differences between the three
groups reached statistical significance (Figure 1, Table 2).
Among the RPF patients, asbestos exposure increased the
risk for both DPT and for all pleural fibrotic changes
(Table 3).
The mean maximum thickness of DPT was 2.8 (SD 1.0)
mm for the 4 unexposed RPF patients, 9.8 (SD 5.1) mm
for the 12 exposed patients with RPF and 5.1 (SD 2.7) mm
for the 7 exposed controls (Figure 2). The difference
between the three groups was significant (P = 0.040), and
a similar difference was found for contralateral pleural
thickening (P = 0.048). The respective values for the con-
tralateral DPT were 2 (SD 0) mm (3 subjects), 6.5 (SD 4.2)
mm (10 subjects), and 2.8 (SD 1.0) mm (4 subjects) (Fig-
ure 2).
Rounded atelectasis was detected in one unexposed RPF
patient (6%), one asbestos-exposed control (6%) and five
asbestos-exposed RPF patients (22%), three of whom had
bilateral findings. No statistical difference was noted (p =
0.182).
In the ordinal logistic regression analysis, the asbestos-
exposed RPF patients had a nonsignificantly increased risk
for the development of DPT when compared with that of
the asbestos-exposed controls (OR 3.06, 95% CI 0.81–Orphanet Journal of Rare Diseases 2008, 3:29 http://www.ojrd.com/content/3/1/29
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11.56). Age at the time of the HRCT, smoking history,
pleural plaques, and lung fibrosis grade had no influence
on the development of DPT (additional file 3).
The four patients with RPF related to the previous use of
ergotamine derivates had no DPT.
Pleural masses
We observed exceptionally large pleural masses in three
asbestos-exposed patients with RPF. The uniform masses
were located anteriorly in the pleural space and continued
into the anterior mediastinum (Figure 3). The overall vol-
umes of these masses clearly differed from the plaques
and DPT found in the other persons. These unique fibrotic
findings were omitted from the DPT thickness assessment,
which was measured from the continuous dorsal fibrotic
sheet.
Lung fibrosis
There was no notable lung fibrosis in the unexposed RPF
patients, but the three groups did not differ statistically in
this respect (Figure 1, Table 2). One asbestos-exposed RPF
patient had mild lung fibrosis (class 2), and two had mod-
erate fibrotic changes (class 3), as did two controls. The
exposed RPF patients were not more susceptible to lung
fibrosis than the asbestos-exposed controls (OR 1.29,
95% CI 0.25–6.63). Lung fibrosis was associated with the
occurrence of pleural plaques (OR 2.73, 95% CI 1.10–
6.78). Age, smoking and DPT did not affect the develop-
ment of lung fibrosis (additional file 3).
Most of the asbestos-exposed RPF patients with DPT also
had bilateral pleural plaques and vice versa. One person
had all three of the distinctive abnormal findings. The
most typical findings of the asbestos-exposed controls
were bilateral pleural plaques, and 1 subject from the con-
trol group had all three notable changes. Twelve (75%) of
the unexposed RPF patients, six (27%) of the asbestos-
exposed RPF patients and six (33%) of the asbestos-
exposed controls did not have any of these changes.
Diffuse pleural thickening, pleural plaques and lung fibrosis Figure 1
Diffuse pleural thickening, pleural plaques and lung fibrosis. Proportion of persons with diffuse pleural thickening 
(DPT) (class ≥ 1), bilateral parietal pleural plaques and lung fibrosis (class ≥ 2) among the unexposed patients with retroperito-
neal fibrosis (RPF), the asbestos-exposed patients with RPF and the asbestos-exposed controls. * Difference between three 
groups, ** Difference between the unexposed and exposed RPF patients P = 0.045.
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Pleural fibrosis at the time of the RPF diagnosis
Using patient's medical files, we were able to evaluate the
presence of pleural fibrosis in 14 out of 17 RPF asbestos-
exposed patients having fibrosis in the current HRCT. At
the time of the RPF diagnosis, eight of them had had
fibrotic changes in their thoracic X-ray and 6 had not. The
subjects having pleural fibrosis at the time of the RPF diag-
nosis had a higher mean score for both PPP (2.8 versus
1.5) and DPT (2.1 versus 1.0) compared with the ones
who had developed pleural changes after the appearance
of RPF. These differences were not of statistical signifi-
cance.
Discussion
This study describes the association between RPF and
asbestos-related lung diseases. We hope that our results
help to identify persons who have developed RPF through
occupational exposure to asbestos. Even though the find-
ings of the current study alone are not enough to declare
a causal association between asbestos exposure and RPF,
they strengthen the validity of the results of our earlier
case-control study and clarify the phenotype of asbestos-
related RPF.
To our knowledge, the literature contains only three
reports describing asbestos-related pleural findings in
altogether five RPF patients [14-16]. In our study 16 out of
22 (73%) asbestos-exposed RPF patients had asbestos-
related pleural pathology in their chest HRCT. The preva-
lence of pleural plaques, DPT and lung fibrosis found in
the asbestos-exposed RPF patients was similar to that
determined for the asbestos-exposed controls, but DPT
was clearly more extensive in the asbestos-exposed RPF
patients. Only a few RPF patients and controls with more
than 10 fiber-years of asbestos exposure had asbestosis. It
seems that the exposure level associated with the develop-
ment of RPF is comparable to that associated with the
Table 2: Parietal pleural plaques, diffuse pleural thickening and lung fibrosis in the patients with retroperitoneal fibrosis (RPF) and the 
asbestos-exposed controls.
Radiological finding RPF without asbestos exposure RPF with asbestos exposure Controls with ≥ 10 fy of asbestos exposure
N = 16
% (N)
<10 fy
N = 13
% (N)
≥ 10 fy
N = 9
% (N)
N = 18
% (N)
Pleural plaques
class 0 68.8 (11) 23.1 (3) 11.1 (1) 22.2 (4)
class 1 19.8 (3) 15.4 (2) 22.2 (2) 27.8 (5)
class 2 12.5 (2) 38.5 (5) 33.3 (3) 27.8 (5)
class 3–5 0 (0) 23.1 (3) 33.3 (3) 22.2 (4)
DPT
class 0 75.0 (12) 46.2 (6) 44.4 (4) 61.1 (11)
class 1 6.3 (1) 0 (0) 11.1 (1) 11.1 (2)
class 2 18.8 (3) 23.1 (3) 0 (0) 33.3 (3)
class 3 0 (0) 30.8 (4) 44.4 (4) 22.2 (2)
Lung fibrosis
class 0 87.5 (14) 69.2 (9) 66.7 (6) 77.8 (14)
class 1 12.5 (2) 15.4 (2) 22.2 (2) 11.1 (2)
class 2 0 (0) 7.7 (1) 0 (0) 0 (0)
class 3–5 0 (0) 7.7 (1) 11.1 (1) 11.1 (2)
(fy = fiber years, DPT = diffuse pleural thickening)
Table 3: Pleural fibrosis consisting of bilateral parietal pleural plaques (PPP) and diffuse pleural thickening (DPT) in the patients with 
retroperitoneal fibrosis (RPF pts) regarding their asbestos exposure
Unexposed RPF pts Asbestos-exposed RPF pts OR (95% CI)
Pleural fibrosis - 10 5
Pleural fibrosis + 6 17 5.7 (1.4 – 23.4)
PPP - 14 8
PPP + 2 14 12.2 (2.2 – 68.2)
DPT - 12 10
DPT + 4 12 3.6 (0.9 – 14.7)
(OR = Odds ratio)Orphanet Journal of Rare Diseases 2008, 3:29 http://www.ojrd.com/content/3/1/29
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development of pleural fibrosis rather than to the high
level of exposure that induces asbestosis.
On the basis of our results, it can be argued that RPF is an
independent risk factor for pleural fibrosis. The results of
the case-control setting (ordinal regression analysis, addi-
tional file 3) indicate that RPF patients are more prone
towards the development of severe DPT than exposed
control subjects. The small number of cases did not allow
us to evaluate the interactions between asbestos and RPF.
Pleural fibrosis was evident at the time of the RPF diagno-
sis in most of the cases. Asbestos exposure occurs mainly
via the respiratory system, and pleural fibrosis is far more
common than RPF. It has been estimated that there are
approximately 200 000 asbestos-exposed people [17], 80
000 men with bilateral pleural plaques, and even more
with DPT [18] and, according to our estimations, 70–100
patients with RPF in Finland. Taking into consideration
these findings, we suggest that asbestos-exposed subjects
with RPF develop concomitant pleural fibrosis because of
their higher individual susceptibility for asbestos-induced
fibrosis.
Parietal pleural plaques are considered pathognomonic
for asbestos exposure, and hence they also serve as an
indicator of past exposure [19]. The clear difference
between the unexposed and exposed groups with a posi-
tive trend in the RPF subgroups with slight and moderate
Maximum thickness of diffuse pleural thickening Figure 2
Maximum thickness of diffuse pleural thickening. Maximum thickness of diffuse pleural thickening (DPT, black dia-
monds), and the respective values for the contralateral pleura (white diamonds), in the unexposed patients with retroperito-
neal fibrosis (RPF), the asbestos-exposed patients with retroperitoneal fibrosis and the asbestos-exposed controls. The lines 
connect each individual's values. "0" indicates that no diffuse pleural thickening was detected.
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Figure 3 (see legend on next page)
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exposure strengthens the validity of the results of our pre-
vious exposure risk assessment [6].
The percentage of bilateral pleural plaques in the asbestos-
exposed groups was similar to those in previous studies,
in which similar asbestos-exposed cohorts in Finland have
been studied with CT scanning or autopsy [20,21]. Two of
the eighteen patients with RPF but assumed to have had
no asbestos exposure, had some bilateral plaques but no
other evaluated abnormalities. This finding probably
reflects a high urban background of amphibole asbestos
anthophyllite, which was previously widely used in Fin-
land and results in a relatively high prevalence of PPP in
the Finnish urban population [21].
DPT was the most frequent among the asbestos-exposed
RPF patients and it was thicker than in the asbestos-
exposed controls or in the unexposed RPF patients. DPT is
thought to be a consequence of acute asbestos-related
pleurisy [22]. However, DPT is not specific to asbestos
exposure and may also result from other inflammatory
conditions, such as infections, trauma, surgery and drug
reactions (eg to ergot derivates) [23]. Crocidolite-related
DPT has been shown to progress in the first 15 years after
its diagnosis [24], and this progression concurs with our
clinical experience in Finland with the past use of amphi-
bole asbestos. We think that the thinner DPT seen in
unexposed RPF patients may be the result of short-lasting
injury such as surgery or infection, and the thicker DPT
found in asbestos-exposed persons is probably related to
continuous irritation caused by bioresistant amphibole
fibers.
Available CT scans of RPF tissue in asbestos-exposed
patients show large unresolved masses that are probably,
for the most part, acellular fibrous tissue resembling the
one found in DPT.
DPT, unlike parietal pleural plaques, causes significant
restrictive impairment of lung function [25,26]. The
latency time for DPT is typically over 20 years from the
beginning of asbestos exposure, although benign asbestos
pleurisy can occur earlier [27]. DPT can be induced by
moderate asbestos exposure, and the amount of exposure
required for the development of DPT is probably higher
than for parietal pleural plaques [28]. Nine out of the
eleven asbestos-exposed patients with RPF and bilateral
DPT also had bilateral pleural plaques (class ≥ 2). Marked
DPT masks parietal plaques, and some patients with class
2 plaques and thick DPT may, in fact, have had bilateral
plaques of class 3.
Ergot drugs have been shown to cause pleural effusion
and DPT [23]. This finding is particularly interesting
because the use of ergotamine derivates is also a well
known risk factor for RPF [29]. In our study, however, the
persons having RPF in relation to the use of ergoline med-
ication had no signs of DPT. The pleural effusion and DPT
induced by asbestos and ergot drugs share common fea-
tures, and the etiological diagnosis is difficult for persons
with both exposures [30].
Three asbestos-exposed RPF patients had exceptionally
large anterior pleural masses extending into the anterior
mediastinum. All of them also had typical asbestos-
related findings: widespread bilateral plaques in all three;
dorsal DPT in two cases (Figure 3A and 3B) and fibrotic
lesions fulfilling the criteria for asbestosis in one case (Fig-
ure 3C, not shown with the parenchymal settings). In all
of these cases the pleural masses were visible in the chest
X-rays taken at the time of the diagnosis of RPF. The coex-
istence of large masses in the pleural and retroperitoneal
space suggests a common etiology, although there was no
continuity between the mediastinal and retroperitoneal
masses. In our experience, such changes are rarely found
even in asbestos-exposed persons having other marked
pleural pathology. Two similar cases having slight asbes-
tos exposure and no other known risk factors for RPF have
been recently reported in France [16]. It seems that asbes-
tos can induce unusually severe fibrotic reaction in some
susceptible individuals.
Our study showed that the frequency of asbestos-related
lung fibrosis in RPF patients was not higher than that of
Pleural masses in the patients with retroperitoneal fibrosis (RPF) Figure 3 (see previous page)
Pleural masses in the patients with retroperitoneal fibrosis (RPF). A: High-resolution computed tomography scan of 
the lung of a 55-year-old former pipefitter with RPF; there is a large anterior pleural mass (maximum dimensions of 30 mm × 
150 mm) continuing into the mediastinum (arrowheads) and a thinner dorsal diffuse pleural thickening (white arrow) with a 
rounded atelectasis (black arrow); the patient had undergone left-sided pleural decortication 10 years earlier. B: An anterior 
mediastinal mass with maximum dimensions of 30 mm in thickness and 190 mm in width (arrowheads), bilateral diffuse pleural 
thickening (white arrows) with a rounded atelectasis on the right side (black arrow); this 62-year-old RPF patient had worked 
as a storeman, had used asbestos gloves and sealing tapes and done some pipe insulation. C: A 76-year-old female with RPF 
worked as a construction cleaner and had had a high level of asbestos exposure; there is a large plaque-like mass with calcifica-
tions with maximum dimensions of 27 mm in thickness and 150 in mm width. A smaller paravertebral plaque (white arrow) has 
no continuity with retroperitoneal fibrosis.Orphanet Journal of Rare Diseases 2008, 3:29 http://www.ojrd.com/content/3/1/29
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the asbestos-exposed controls. It has been widely accepted
that the development of asbestosis requires high-level
asbestos exposure, a minimum of 20–25 fiber-years [31].
Most of our patients and the controls had exposure of <20
fiber-years, and, therefore, the proportion of persons with
asbestosis was low.
Although we propose that pleural and retroperitoneal
fibrosis may both be caused by asbestos fibers, there are
certain differences in the clinical picture of pleural fibrosis
and RPF. RPF is usually symptomatic, causing poorly
localized pain in the abdominal, flank, or back region.
Symptoms and laboratory findings suggesting systemic
inflammation–weight loss, fever and nausea, a clearly ele-
vated erythrocyte sedimentation rate and anaemia–are
frequently present [32]. DPT usually progresses slowly
and is asymptomatic in many cases, and parietal plaques
cause no symptoms. Only patients with acute asbestos
pleurisy may have local and systemic symptoms and a
moderately elevated erythrocyte sedimentation rate [27].
Corticosteroids usually have a dramatic effect on inflam-
mation in RPF, and together with surgical management of
ureteric obstruction are the mainstay treatment for RPF
[33]. Corticosteroids have no role in the management of
DPT, but may alleviate the symptoms of acute asbestos
pleurisy.
Albeit our study population is one of the largest published
sets of RPF patients in the literature, the numbers of par-
ticipants in our study was still rather small. Therefore we
combined the groups of RPF patients with slight and
moderate-to-high asbestos exposure. This combined
group of RPF patients had, on the average, less asbestos
exposure than the control group with exposure of ≥ 10
fiber-years in all cases. The ordinal logistic regression
modeling may, therefore, have underestimated the risk of
pleural fibrosis in association with RPF.
On the basis of our epidemiologic work and our current
study we propose the following criteria for the classifica-
tion of RPF as an occupational disease: (i) occupational
asbestos exposure of ≥ 10 fiber-years (OR 8.8) or (ii) occu-
pational asbestos exposure of <10 fiber-years (OR 5.5)
combined with bilateral pleural plaques or DPT or both
pleural plaques and DPT. The presence of asbestosis
(parenchymal fibrosis) should not to be required for the
diagnosis of asbestos-related RPF. Asbestos-related RPF,
like asbestos-related pleurisy, should be a diagnosis of
exclusion. Nevertheless, asbestos-related pleural findings
should be taken into account also in the presence of other
risk factors, such as ergotamine medication or abdominal
aortic aneurysm.
Conclusion
In conclusion, the majority of the asbestos-exposed
patients with RPF had asbestos-related pleural fibrosis
and it was more extensive than in the asbestos-exposed
controls. Lung fibrosis was equally frequent among the
asbestos-exposed RPF patients and the controls. RPF with-
out asbestos exposure had no association with pleural or
lung fibrosis.
The findings suggest a shared etiology for RPF and pleural
fibrosis and possibly similar pathogenetic mechanisms in
some subjects. All RPF patients should be evaluated for
asbestos exposure, and lung HRCT should be performed if
appropriate.
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